| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5c564991ae13d25b7772e76de8d0160e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5c9ef208c8453e0a85a84bfbd5d8fdf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_354bc0777afcc4fd4b9218efba1151cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e44b9892acc24cb69b76424b3ddd675d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_faf522b8b83eded745c73018576219ba |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2007-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db6fce9b351aaec895db36faff0a8eca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_519a2eae7b7d1a69b673b40dd36dbf80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1dc62c1eb46d1ea993d0d2160baf0a0 |
| publicationDate |
2007-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2007123247-A1 |
| titleOfInvention |
NMU-GHSR1b/NTSR1 ONCOGENIC SIGNALING PATHWAY AS A THERAPEUTIC TARGET FOR LUNG CANCER |
| abstract |
The present invention relates to a method of and a kit for assessing the prognosis of lung cancer by detecting the expression level of the neuromedin U (NMU) gene in a patient-derived biological sample. The method and kit are particularly preferred for assessing the prognosis of non-small cell lung cancer (NSCLC). Furthermore, the present invention relates to a method of screening for a therapeutic agent for cancer, in particular, lung cancer, by detecting compounds that inhibit the binding of the NMU protein with the heterodimer of growth hormone secretagogue receptor 1b (GHSR1b) and neurotensin receptor 1 (NTSR1). |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8569244-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8617562-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9073968-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9415096-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2496150-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110195058-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112980957-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112980957-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014087387-A1 |
| priorityDate |
2006-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |